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Abstract
Aims: Liraglutide, a GLP-1 receptor agonist, regulates appetite via receptors in the brain. Due to concerns over the potential of centrally-acting anti-obesity medications to affect mental health, pooled neuropsychiatric safety data from all phase 2 and 3a randomized, double-blind trials with liraglutide 3.0 mg were evaluated post hoc.
Methods: Data from the liraglutide weight-management programme were pooled. Across trials, individuals with a body mass index ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidities were randomized to once-daily subcutaneous liraglutide 3.0 mg (n=3384) or placebo (n=1941), both with a 500 kcal/day deficit diet plus exercise. Adverse events related to neuropsychiatric safety were collected in all trials. Additionally, in the phase 3a trials, validated mental-health questionnaires were prospectively and systematically administered. 
Results: In the pooled analysis of 5325 randomized and exposed individuals, rates of depression (2.1 versus 2.1 events/100 person-years) and anxiety (1.9 versus 1.7 events/100 person-years) through adverse event reporting were similarly low in the liraglutide group and the placebo group. Nine (0.3%) individuals on liraglutide and two (0.1%) on placebo reported adverse events of suicidal ideation or behaviour. In phase 3a trials, mean baseline Patient Health Questionnaire-9 scores of 2.8±3.0 versus 2.9±3.1 for liraglutide versus placebo improved to 1.8±2.7 versus 1.9±2.7 at treatment end; 34/3291 individuals (1.0%) on liraglutide 3.0 mg versus 19/1843 (1.0%) on placebo reported suicidal ideation on the Columbia-Suicide Severity Rating Scale.
Conclusions: The results of this exploratory pooled analysis do not provide any cause for concern regarding the neuropsychiatric safety of treatment with liraglutide 3.0 mg in patients similar to those individuals included in the examined trials. Although there was a small numerical imbalance in suicidal ideation with liraglutide through adverse event reporting, no between-treatment imbalances in suicidal ideation/behaviour or depression were noted through prospective questionnaire assessments. 
Introduction
Obesity is a global health problem [1] and is associated with multiple comorbidities  ADDIN REFMGR.CITE [2,3], premature mortality  ADDIN REFMGR.CITE [4], impaired health-related quality of life  ADDIN REFMGR.CITE [5], and individual, societal and economic costs  ADDIN REFMGR.CITE [6]. While initially effective for many individuals, diet or behaviour modification alone is often difficult to sustain and many individuals regain weight on discontinuation [2]. Pharmacotherapy for chronic weight management may serve as an adjunct to lifestyle intervention in enabling individuals to achieve and sustain clinically relevant weight loss. 

Given that many of the approved anti-obesity medications are centrally-acting appetite suppressants, neuropsychiatric safety has become an area of interest  ADDIN REFMGR.CITE [7-9]. Rimonabant, the first selective central cannabinoid (CB1) receptor antagonist, was never approved by the Food and Drug Administration (FDA) due to concerns over psychiatric adverse events, including depression, anxiety, and suicidal ideation [10]. Rimonabant was withdrawn by the European Medicines Agency (EMA) in 2009, leading to the termination of the development of several CB1-receptor blockers for the treatment of obesity  ADDIN REFMGR.CITE [11,12]. However, many potential treatments aimed at varied molecular targets in the central nervous system (CNS) are still under development  ADDIN REFMGR.CITE [8,9,11]. Adding to the complexity of the situation is the fact that, in general, people with obesity have a higher prevalence of neuropsychiatric disorders, such as depression, compared to the general population  ADDIN REFMGR.CITE [13,14].

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that regulates appetite centrally via receptors in the hypothalamus and other brain areas [15]. Weight loss with liraglutide is mediated by reduced appetite and energy intake rather than by increased energy expenditure [16]. The clinical development programme for liraglutide in weight management comprised one phase 2 dose-finding trial, which demonstrated weight loss with liraglutide doses up to 3.0 mg over 2 years [17], and a large global phase 3a programme called SCALE: Satiety and Clinical Adiposity – Liraglutide Evidence in individuals with and without diabetes. The SCALE programme was designed to investigate the efficacy and safety of liraglutide 3.0 mg in four randomized, double-blind, placebo-controlled trials (one of 3 years’ duration, two of 56 weeks, one of 32 weeks) in over 5300 adults. Treatment with liraglutide 3.0 mg led to observed mean weight loss from baseline ranging from 5.7 to 8.0% (6.0–8.4 kg) depending on the SCALE trial, whereas mean weight loss in the placebo group ranged from 0.1 to 2.6% (0.1–2.8 kg)  ADDIN REFMGR.CITE [18-21]. Liraglutide, administered as a once-daily subcutaneous dose of 3.0 mg, is now approved for weight management in several regions, including North America and Europe.

This post hoc analysis evaluates pooled neuropsychiatric safety data from the five randomized, double-blind and placebo-controlled trials described above, including data from two mental health questionnaires that were used in the four SCALE trials. Due to evolving regulatory and safety concerns described above, psychiatric disorders were identified as medical events of special interest in the phase 3a liraglutide 3.0 mg clinical development programme, providing an opportunity for prospective evaluation of depression and suicidality.
Methods
This is a post hoc analysis and comprehensive report of pooled neuropsychiatric safety data from the liraglutide weight management programme. The five trials were performed at clinical research sites in accordance with the Declaration of Helsinki [22] and Good Clinical Practice guidelines [23], and the respective protocols were approved by local institutional review boards or ethics committees. All participants provided written informed consent before the trials began. See Table S1, Supporting Information, for further information about the trials, including inclusion/exclusion criteria and primary endpoints; full methodology details have been reported previously  ADDIN REFMGR.CITE [18-21,24]. 

Participants
Each trial enrolled men and women with a body mass index (BMI) of ≥27 kg/m2 with at least one weight-related comorbidity, or a BMI of ≥30 kg/m2 (Table S1). Key exclusion criteria included type 1 or 2 diabetes (except for the SCALE Diabetes trial which specifically enrolled individuals with type 2 diabetes), the use of medications causing significant weight gain or loss, previous bariatric surgery, and a history of chronic pancreatitis or idiopathic acute pancreatitis. Psychiatric illness was not excluded in the phase 2 trial, as this was not a regulatory requirement at the time, but individuals were excluded from the phase 3a trials if they had: a history of major depressive disorder within the last 2 years; a Patient Health Questionnaire-9 (PHQ-9) score ≥15 (indicating moderately severe/severe depression) at screening; a history of other severe psychiatric disorders; a lifetime history of a suicide attempt; or a history of suicidal behaviour or suicidal ideation type 4 (active suicidal ideation with some intent to act without specific plan) or 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the month before randomization. 

Interventions
All participants self-administered treatment with once-daily subcutaneous liraglutide or placebo in FlexPen devices (Novo Nordisk A/S, Bagsværd, Denmark), starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg. This pooled analysis compared data with liraglutide 3.0 mg and placebo only; additional liraglutide doses were investigated in the phase 2 dose-finding trial (1.2, 1.8 and 2.4 mg) and the SCALE Diabetes trial (1.8 mg), but those doses were not included in this analysis since they are not approved for weight management. Furthermore, for the phase 2 trial, only data up to one year were included for liraglutide 3.0 mg and placebo; after that all liraglutide or placebo-treated individuals switched to treatment with liraglutide 2.4 mg and thereafter to 3.0 mg [17]. Diet and exercise counselling, provided at approximately monthly intervals, was similar across the trials  ADDIN REFMGR.CITE [18-21,24]. Participants were advised (in groups or individually) to follow a reduced-calorie diet with an energy deficit of ~500 kcal/day below their estimated total energy expenditure, containing a maximum of 30% energy from fat, ~20% from protein and ~50% from carbohydrates. The diet was reinforced by the use of 3-day food diaries, and pedometers were provided to encourage participants to achieve a recommended minimum of 150 minutes/week of physical activity.

Neuropsychiatric Safety
In each trial, adverse events in the system organ classes of ‘psychiatric disorders’ and ‘nervous system disorders’ were identified using the MedDRA (Medical Dictionary for Regulatory Activities) coding. In the phase 3a trials, psychiatric disorders were classified as medical events of special interest to ensure that brief narratives were collected also for non-serious adverse events. These narratives were limited to a free-text description of the event by the investigator, such as relevant medical history.

In the phase 3a trials, two validated mental health questionnaires were employed for detecting possible depression (PHQ-9 [25]) or suicidal ideation and behaviour (C-SSRS [26]). These were completed at screening, randomization and each visit to the clinic during treatment (except the dose-titration visits in the SCALE Maintenance trial) and each took approximately 10 minutes to complete. Suicidal behaviour was defined as: 1) death by suicide, 2) suicidal attempts where there was intention to die, or 3) nonfatal, self-injurious acts committed without intent to die.

The PHQ-9 was self-administered and consisted of 9 questions used for detecting possible depression and monitoring treatment [25]. The C-SSRS (available at http://www.cssrs.columbia.edu/ (​http:​/​​/​www.cssrs.columbia.edu​/​​)) was administered as an interview by the investigator or sufficiently trained medical personnel [26]. The investigator reviewed the PHQ-9 and C-SSRS questionnaires for completeness together with any reported adverse events at each visit.

Statistical Analyses
All available randomized individuals receiving at least one treatment dose of liraglutide 3.0 mg or placebo from the 5 randomized, controlled weight management trials were included in the analyses. For the change from baseline to end-of-treatment in the PHQ-9 total score, a treatment difference was estimated using an ANCOVA model that included the baseline PHQ-9 total score as a covariate and treatment and trial as factors. None of the trials were powered to identify differences in adverse event rates, hence adverse events were analyzed using descriptive statistics and no testing for significance was done.
Results
Participant Characteristics
Baseline characteristics of the 5325 randomized and exposed individuals are displayed in Table 1, and were generally comparable for liraglutide 3.0 mg and placebo. At baseline, 9.1% of individuals in the liraglutide 3.0 mg group and 10.6% of those in the placebo group had a self-reported history of depression, and 7.2% versus 7.8% had a self-reported history of anxiety. None had a history of suicide attempt or self-injury.

Neuropsychiatric Safety Data by Adverse Event Reporting
Adverse Events
Adverse events in the system organ classes of psychiatric and nervous system disorders in the pooled analysis across all 5 trials are shown in Table 2. Overall psychiatric disorder rates were similar for liraglutide 3.0 mg and placebo. Most events were non-serious and did not lead to participant withdrawal. Rates of depression, anxiety and insomnia were similarly low for both treatments (Table 2), though insomnia rates were marginally higher in the liraglutide group. 

Suicidal Ideation and Behaviour 
Nine of 3384 individuals (0.3%, 0.2 events per 100 person-years) in the liraglutide 3.0 mg group versus 2 of 1941 (0.1%, <0.1 events per 100 person-years) in the placebo group reported adverse events of suicidal ideation or behaviour. All except three individuals continued on treatment and all except one recovered from the events. The condition of the individual who did not recover was considered chronic but stable at the end of the study. Importantly, at the final trial visit, it was discovered that this participant had a history of a suicide attempt 12 years prior to study enrolment, and thus, based on exclusion criteria, should not have been enrolled. Weight loss at the time of the event for each individual is shown in Table S2, Supporting Information. Of the 11 individuals reporting suicidal ideation or behaviour, all except one in each treatment group (liraglutide, suicidal ideation event; placebo, suicide attempt) reported having a past history of psychiatric disorders (including major depression, depression, anxiety and insomnia) or life stressors accompanying the events; see Table S2, Supporting Information for details. Ten of the 11 individuals were from the SCALE Obesity and Prediabetes trial and 9 had prediabetes. Two of the 11 individuals reported 2 events each, making 13 events in total. Of these 13 events, 7 occurred after the first year of the SCALE Obesity and Prediabetes trial.

Neuropsychiatric Safety Data through Prospective Collection of Mental Health Questionnaires
Two validated mental health questionnaires were employed in the phase 3a trials, the PHQ-9 and the C-SSRS. 

Patient Health Questionnaire-9 (PHQ-9)
Mean±SD PHQ-9 scores at baseline were 2.8±3.0 (range 0-14) with liraglutide 3.0 mg versus 2.9±3.1 (range 0-17) with placebo. Mean PHQ-9 scores improved (decreased) to 1.8±2.7 versus 1.9±2.7, respectively, at end-of-treatment (using last-observation-carried-forward imputation), with an estimated treatment difference (95% confidence interval) of -0.02 (-0.17 to 0.12). The mean maximum post-baseline scores were 4.2±3.7 and 4.0±3.8 for liraglutide versus placebo, respectively. Examining the highest PHQ-9 score observed at any time during treatment for each participant, 8.3% versus 8.5% of individuals scored ≥10 (moderate depression or worse) and 1.9% versus 2.0% scored ≥15 (moderately severe depression or worse) with liraglutide 3.0 mg versus placebo. Treatment groups were similar in the proportions of participants showing improvement or worsening from baseline to their maximum total PHQ‑9 score at any time of treatment (Table 3).

Mental health questionnaire information for the individuals reporting suicide-related adverse events is shown in Table S3, Supporting Information. PHQ-9 total scores at baseline indicated no or mild depression for all 11 individuals. Eight of the 11 individuals had increases during treatment in their maximum PHQ-9 score from baseline, with 2 scores in the moderately severe or severe depression category. The maximum post-baseline response to question 9 of the PHQ-9 (‘Over the last two weeks how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?’) was 0 for 7 of the 11 individuals (5 in the liraglutide group and both individuals in the placebo group), indicating a response of ‘not at all’, 1 for 3 individuals in the liraglutide group, indicating ‘several days’ and 3 for 1 individual in the liraglutide group, indicating ‘nearly every day’; see the Supplemental Results for details. 

Columbia-Suicide Severity Rating Scale (C-SSRS)
On the C-SSRS at baseline, 110 individuals (3.3%) in the liraglutide 3.0 mg group versus 67 (3.6%) in the placebo group reported suicidal behaviour and/or ideation at some time during their life. Most cases were of suicidal ideation, while 6 (0.2%) versus 2 (0.1%) individuals, respectively, reported suicidal behaviour. The above individuals were not excluded from the trials as the reported behaviour did not occur in the month before randomization, as per exclusion criteria. During treatment, 34 individuals (1.0%) on liraglutide 3.0 mg versus 19 (1.0%) on placebo reported suicidal ideation on the C-SSRS (Table 4). Most of these individuals (26/34, 76% in the liraglutide group and 19/19, 100% in the placebo group) did not report accompanying suicidal ideation adverse events.
 
For the 11 individuals reporting suicidal ideation or behaviour adverse events, only 1 of 9 individuals in the liraglutide 3.0 mg group reported suicidal ideation at baseline on the C-SSRS. Neither of the 2 in the placebo group did so, and no individuals in either group reported suicidal behaviour on the C-SSRS at baseline. The individual who reported suicidal ideation at baseline was not excluded as the ideation did not occur in the month before randomization. The C-SSRS captured suicidal ideation during treatment in 8 of the 11 individuals who reported such events (Table S3, Supporting Information). The 3 individuals for whom events were not captured by C-SSRS included 1 in the liraglutide group who reported depression with suicidal ideation, and the 2 individuals in the placebo group who reported a suicide attempt and a major depressive episode with contemplation about suicide, respectively. The C-SSRS did not capture the suicidal behaviour in either of the 2 individuals who reported a suicide attempt.

Neuropsychiatric Safety Data following Treatment Discontinuation
All of the SCALE trials, except the SCALE Sleep Apnoea trial, had a 12-week off-treatment observational follow-up period to evaluate withdrawal or rebound effects of discontinuing liraglutide treatment. No neuropsychiatric safety signals, through adverse event reporting, PHQ-9 or C-SSRS data collection at the end of the 12-week time period, were evident to indicate any withdrawal or rebound effects.
Discussion
This was a pooled post hoc analysis of neuropsychiatric safety data across weight management trials with liraglutide 3.0 mg. The overall incidence of depression, anxiety and insomnia adverse events was similarly low (≤3.6%) in both liraglutide 3.0 mg and placebo treatment groups, with a small numerical imbalance not favouring liraglutide in insomnia events and in suicidality ideation/behaviour. However, there were no differences in depression or suicidality indicators when prospectively assessed in the phase 3a programme, which excluded individuals with a history of severe psychiatric disorders or suicidal ideation/behaviour, as reflected by detailed analysis of PHQ-9 scores and categories, and C-SSRS data. Furthermore, there was no indication of withdrawal or rebound adverse effects when liraglutide treatment was discontinued.

Nine (0.3%) versus two (0.1%) individuals reported suicidal ideation or behaviour adverse events; eight of the eleven individuals continued on treatment and symptoms resolved in ten. The individual who did not recover from suicidal ideation was randomized in error as she had a history of a suicide attempt 12 years previously; her condition was considered chronic but stable at the end of the trial. Nine of the eleven individuals had prediabetes, which, together with diabetes, has been shown to be associated with symptoms of depression [27]; however, no individuals from the SCALE Diabetes trial reported suicidal ideation/behaviour events. Nine of the eleven individuals had a history of psychiatric disorders or life stressors accompanying the events. Overall, no evidence suggests that a positive history of these types of events should be a contraindication for treatment with liraglutide.  

Several studies have revealed positive associations between BMI and some psychiatric disorders, including depression and anxiety  ADDIN REFMGR.CITE [14], with some differences between men and women [13]. In one epidemiological study, individuals with obesity were 1.5 times more likely to report such disorders occurring during their lifetime or in the past year than those of normal weight, and anxiety rates were increased not only in individuals with obesity, but also in those who were moderately overweight [28]. Individuals with obesity are also more likely to experience insomnia according to a recent review [29]. There appears to be a reciprocal link between depression and obesity [30], whereby obesity can increase the risk of depression and, conversely, depression can predict the development of obesity  ADDIN REFMGR.CITE [31]. It is therefore important that pharmacological treatment options for chronic weight management are available that will not exacerbate depression and can be used safely with antidepressants. As with this trial, no signal for neuropsychiatric events was detected in trials of liraglutide at doses up to 1.8 mg for management of hyperglycaemia in individuals with type 2 diabetes, including the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial  ADDIN REFMGR.CITE [34,35], or in postmarketing surveillance. Nevertheless, and in accordance with regulatory guidance, the US prescribing information states that patients treated with liraglutide 3.0 mg should be monitored for depression or suicidal thoughts, and treatment should be discontinued if symptoms develop; treatment should also be avoided in patients with a history of suicidal attempts or active suicidal ideation. However, no such text is included in the European summary of product characteristics.

We note that the information obtained from the adverse-event reporting and that from the questionnaires used in the SCALE trials were not always concordant, even though the data were collected during the same visits throughout the trials. For example, while a similar proportion of individuals in the liraglutide 3.0 mg group (1.0%) and the placebo group (1.0%) reported suicidal ideation on the C-SSRS, far fewer individuals in both treatment groups reported adverse events of suicidal ideation or behaviour. Furthermore, although 8 of the 11 individuals who reported suicidal ideation or behaviour adverse events had increases in their maximum total PHQ-9 scores during treatment, these increased scores were in the moderately severe or severe depression range in only two cases. The suicidal ideation events were detected by the C-SSRS for 8 of the 11 individuals, all in the liraglutide group, whereas neither adverse event of suicidal behaviour (attempt) was detected by C-SSRS. Thus, longitudinal assessment of neuropsychiatric safety in clinical trials may benefit from the combination of adverse event reporting and validated questionnaires, as shown here.

A limitation of this analysis is that it was performed on a population that was selected based on trial-specific eligibility criteria, and does not necessarily cover the full spectrum of patients that might be treated outside of clinical trials, as individuals at high-risk for psychiatric disorders were excluded. Furthermore, the trial was not powered to quantify a treatment effect on the event rate of psychiatric disorders, suggesting the importance of further investigation. While the PHQ-9 and the C-SSRS are validated mental-health questionnaires and may be useful as rapid assessment screening tools, their limitations compared to more lengthy structured assessments should also be noted. Strengths of the analysis include the overall large sample size and substantial exposure to liraglutide 3.0 mg in the blinded trials, and the systematic prospective collection of neuropsychiatric safety data by trained staff. 

In conclusion, the results of this exploratory pooled analysis of neuropsychiatric safety data from the liraglutide 3.0 mg weight management clinical development programme do not provide any clear cause for concern regarding liraglutide 3.0 mg treatment in patients similar to those individuals included in the examined trials. Although there was a small numerical imbalance in suicidal ideation with liraglutide as indicated through adverse event reporting, no between-treatment imbalances in suicidal ideation/behaviour or depression were noted through prospective questionnaire assessments. The long-term safety and efficacy of anti-obesity medications are important as individuals with obesity often require sustained therapy to achieve and maintain weight loss. Neuropsychiatric safety should be an integral component of any clinical risk/benefit assessment, and the data provided here can contribute to thoughtful and objective decision-making and dialogue between patients and clinicians.
Acknowledgements
Novo Nordisk A/S funded the trials and also provided the trial products. The contribution of all trial participants and the trial site personnel who helped conduct the trials is gratefully acknowledged. We would also like to thank Michael Taulo Lund, M.D., Ph.D. and Hanna Hedman, Ph.D. (both Novo Nordisk) for contributing to the manuscript reviews, as well as Angela Stocks, Ph.D. (Larix A/S, Copenhagen, Denmark) for editorial and medical writing services, which were funded by Novo Nordisk.
Conflict of Interest
P.O. has received funding for research from Orexigen Therapeutics, Weight Watchers International and Novo Nordisk, honoraria from Novo Nordisk and Medscape/WebMD and has been an advisory board member for Orexigen Therapeutics, Janssen and Pfizer. V.A. has received funding for research from AstraZeneca/BMS, Calibra, Eisai, Elcelyx, Janssen, Novo Nordisk, Sanofi, and Theracos and has received consultancy fees from Adocia, ADA, AstraZeneca, Janssen, Medscape, Novo Nordisk, Sanofi, and Tufts, all within the last 12 months. A.A. has been an advisory board member for BioCare, consultant for Basic Research, Gelesis, Novo Nordisk, Omega ACO, Pathway Genomics, Pfizer, Sanofi-Aventis and S-Biotek  and a recipient of travel expenses and/or modest honoraria (<$2,000) for lectures given at national and international meetings, often with support from one or more corporate sponsors. He is co-inventor of a number of patents owned by the University of Copenhagen, in accordance with Danish law, member of the board and shareholder in the consultancy company Dentacom Aps, Denmark, and co-founder and co-owner of the University of Copenhagen spin-out company, Mobile Fitness A/S, Denmark. He is also co-founder, co-owner and member of the board of the University of Copenhagen spin-out company Flaxslim ApS, Denmark.
R.K. serves on the advisory boards for Novo Nordisk, Weight Watchers, Retrofit and Zafgen, and has received grant support, on behalf of Northwestern University, from Aspire Bariatrics, Eisai and Novo Nordisk. D.L. has received research funding from AstraZeneca, Boehringer-Ingelheim and Novo Nordisk, and has received consultancy fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Sanofi and Shire, and lecture fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Merck and Novo Nordisk. T.W. serves on advisory boards for Novo Nordisk, Nutrisystem, and Weight Watchers and has received grant support, on behalf of the University of Pennsylvania, from Eisai Co. and Novo Nordisk. J. B. and A. C. are employed by and hold stock in Novo Nordisk. J.W. has received grant funding (via his institution), consultancy and lecture fees (institutional and personal) from Novo Nordisk, and consultancy and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Orexigen and Sanofi (both institutional and personal) in relation to treatments for obesity and/or diabetes. 
Novo Nordisk provided overall management of the trials, performed the statistical analyses and verified the accuracy of the presented data. Novo Nordisk was also responsible for the overall trial designs, and provided a formal review of the manuscript, but the authors had final authority, including choice of journal. Under the direction of the authors and according to an agreed outline, the medical writer, Angela Stocks, drafted the initial version of the manuscript. A.A. participated in the concept and design of the phase 2 trial. A. A. and T. W. were signatory investigators on the phase 2 trial and the SCALE Maintenance trial, respectively, and P. O., V. A., R. K., D. L. and J. W. were also trial investigators. All authors were involved in the analysis or interpretation of the data, and all critically reviewed the manuscript and approved the final version for submission. All authors also agreed to be accountable for all aspects of the work.
Supporting Information
Additional Supporting Information may be found in the online version of this article:
Supplementary results.
Table S1. Summary of randomized, placebo-controlled trials included in the pooled analysis.
Table S2. Information on individuals reporting suicidality adverse events.
Table S3. Questionnaire information for individuals reporting suicidality adverse events.
References
	1. 	NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016; 387:1377-1396.	2. 	Ferguson, C, David, S, Divine, L, Kahan, S., Gallagher, C, Gooding, M, and Markell, P. Obesity Drug Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic Intervention. http://sphhs.gwu.edu/releases/obesitydrugmeasures.pdf . 14-8-2012.  Department of Health Policy,School of Public Health and Health Services, The George Washington University. 	3. 	Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:doi:10.1186/1471-2458-9-88.	4. 	Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71-82.	5. 	Garner R.E., Feeny D.H., Thompson A. et al. Bodyweight, gender, and quality of life: a population-based longitudinal study. Qual Life Res 2012; 21:813-825.	6. 	Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260.	7. 	Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry. Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials (Draft Guidance). http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf . 2012. 	8. 	Rodgers R.J., Tschop M.H., Wilding J.P. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5:621-626.	9. 	Kang J.G., Park C. Anti-obesity drugs: a review about their effects and safety. Diabetes & Metabolism Journal 2012; 36:13-25.	10. 	Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370:1706-1713.	11. 	Sargent B.J., Moore N.A. New central targets for the treatment of obesity. Br J Clin Pharmacol 2009; 68:852-860.	12. 	Aronne L.J., Tonstad S., Moreno M. et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010; 34:919-935.	13. 	Zhao G., Ford E.S., Dhingra S., Li C., Strine T.W., Mokdad A.H. Depression and anxiety among US adults: associations with body mass index. Internation Journal of Obesity 2009; 33:257-266.	14. 	Scott K.M., Bruffaerts R., Simon G.E. et al. Obesity and mental disorders in the general population: results from the world mental health surveys. Int J Obes (Lond) 2008; 32:192-200.	15. 	Knudsen L.B., Secher A., Hecksher-Sorensen J., Pyke C. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. Journal of Diabetes Investigation 2016; 7:56-63.	16. 	van Can J., Sloth B, Jensen CB, Flint A, Blaak EE S.W. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38:784-793.	17. 	Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E. Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.	18. 	Pi-Sunyer X., Astrup A., Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373:11-22.	19. 	Davies M.J., Bergenstal R., Bode B. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes randomized clinical trial. JAMA 2015; 314:687-699.	20. 	Wadden T.A., Hollander P., Klein S. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 2013; 37:1443-1451.	21. 	Blackman A., Foster G., Zammit G. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016; 40:1310-1319.	22. 	World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000; 284:3043-3045.	23. 	International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 2003. 	24. 	Astrup A., Carraro R., Finer N. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.	25. 	Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613.	26. 	Posner K., Brown G.K., Stanley B. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266-1277.	27. 	Mezuk B., Lee H., Abdou C.M. et al. Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychology 2013; 32:254-263.	28. 	Petry N.M., Barry D., Pietrzak R.H., Wagner J.A. Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2008; 70:288-297.	29. 	Hargens T.A., Kaleth A.S., Edwards E.S., Butner K.L. Association between sleep disorders, obesity, and exercise: a review. Nature and Science of Sleep 2013; 5:27-35.	30. 	Bornstein S.R., Schuppenies A., Wong M.L., Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Molecular Psychiatry 2006; 11:892-902.	31. 	Luppino F.S., de Wit L.M., Bouvy P.F. et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67:220-229.	32. 	Li M., Cheung B. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68:804-810.	33. 	Cheung B.M.Y., Cheung T.T., Samaranayake N.R. Safety of antiobesity drugs. Ther Adv Drug Saf 2013; 4:171-181.	34. 	Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311-322.	35. 	Blonde L., Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11 Suppl 3:26-34.
	2. 	Ferguson, C, David, S, Divine, L, Kahan, S., Gallagher, C, Gooding, M, and Markell, P. Obesity Drug Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic Intervention. http://sphhs.gwu.edu/releases/obesitydrugmeasures.pdf . 14-8-2012.  Department of Health Policy,School of Public Health and Health Services, The George Washington University. 
	3. 	Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:doi:10.1186/1471-2458-9-88.
	4. 	Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71-82.
	5. 	Garner R.E., Feeny D.H., Thompson A. et al. Bodyweight, gender, and quality of life: a population-based longitudinal study. Qual Life Res 2012; 21:813-825.
	6. 	Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260.
	7. 	Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry. Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials (Draft Guidance). http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf . 2012. 
	8. 	Rodgers R.J., Tschop M.H., Wilding J.P. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5:621-626.
	9. 	Kang J.G., Park C. Anti-obesity drugs: a review about their effects and safety. Diabetes & Metabolism Journal 2012; 36:13-25.
	10. 	Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370:1706-1713.
	11. 	Sargent B.J., Moore N.A. New central targets for the treatment of obesity. Br J Clin Pharmacol 2009; 68:852-860.
	12. 	Aronne L.J., Tonstad S., Moreno M. et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010; 34:919-935.
	13. 	Zhao G., Ford E.S., Dhingra S., Li C., Strine T.W., Mokdad A.H. Depression and anxiety among US adults: associations with body mass index. Internation Journal of Obesity 2009; 33:257-266.
	14. 	Scott K.M., Bruffaerts R., Simon G.E. et al. Obesity and mental disorders in the general population: results from the world mental health surveys. Int J Obes (Lond) 2008; 32:192-200.
	15. 	Knudsen L.B., Secher A., Hecksher-Sorensen J., Pyke C. Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. Journal of Diabetes Investigation 2016; 7:56-63.
	16. 	van Can J., Sloth B, Jensen CB, Flint A, Blaak EE S.W. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38:784-793.
	17. 	Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E. Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.
	18. 	Pi-Sunyer X., Astrup A., Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373:11-22.
	19. 	Davies M.J., Bergenstal R., Bode B. et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes randomized clinical trial. JAMA 2015; 314:687-699.
	20. 	Wadden T.A., Hollander P., Klein S. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 2013; 37:1443-1451.
	21. 	Blackman A., Foster G., Zammit G. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016; 40:1310-1319.
	22. 	World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000; 284:3043-3045.
	23. 	International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 2003. 
	24. 	Astrup A., Carraro R., Finer N. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.
	25. 	Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613.
	26. 	Posner K., Brown G.K., Stanley B. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266-1277.
	27. 	Mezuk B., Lee H., Abdou C.M. et al. Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychology 2013; 32:254-263.
	28. 	Petry N.M., Barry D., Pietrzak R.H., Wagner J.A. Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2008; 70:288-297.
	29. 	Hargens T.A., Kaleth A.S., Edwards E.S., Butner K.L. Association between sleep disorders, obesity, and exercise: a review. Nature and Science of Sleep 2013; 5:27-35.
	30. 	Bornstein S.R., Schuppenies A., Wong M.L., Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Molecular Psychiatry 2006; 11:892-902.
	31. 	Luppino F.S., de Wit L.M., Bouvy P.F. et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67:220-229.
	32. 	Li M., Cheung B. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68:804-810.
	33. 	Cheung B.M.Y., Cheung T.T., Samaranayake N.R. Safety of antiobesity drugs. Ther Adv Drug Saf 2013; 4:171-181.
	34. 	Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311-322.
	35. 	Blonde L., Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11 Suppl 3:26-34.





Tables
Table 1. Demographics and baseline characteristics. 

Pooled trialsa	Liraglutide 3.0 mg 
N = 3384	Placebo
N = 1941
Sex, n (%)		
   Female	2449 (72.4)	1374 (70.8)
   Male	935 (27.6)	567 (29.2)
Age, years	46.6 (12.2)	46.6 (11.8)
Race, n (%)		
   White	2845 (84.1)	1651 (85.1)
   Black/African-American	348 (10.3)	202 (10.4)
   Asian	115 (3.4)	53 (2.7)
   American Indian or Alaska Native	9 (0.3)	4 (0.2)
   Native Hawaiian or Other Pacific Islander	5 (0.1)	4 (0.2)
   Other	62 (1.8)	27 (1.4)
Ethnicity, n (%)		
   Hispanic	341 (10.1)	193 (9.9)
Body weight, kg	106.1 (21.4)	106.2 (22.2)
Body mass index, kg/m2	37.9 (6.4)	37.8 (6.5)
HbA1c, %b	5.6 (0.4)	5.6 (0.4)
Fasting plasma glucose, mmol/Lb	5.3 (0.6)	5.4 ( 0.6)
History of psychiatric disorder, n (%)	454 (13.4)	307 (15.8)
   Depression (except suicide and self-injury)	309 (9.1)	206 (10.6)
   Suicide and self-injury	0 (0.0)	0 (0.0)
   Anxiety	243 (7.2)	151 (7.8)
On antidepressants, n (%)	306 (9.0)	197 (10.1)
On anxiolytics, n (%)	91 (2.7)	53 (2.7)
Dyslipidaemia, n (%)	1166 (34.5)	618 (31.8)
Hypertension, n (%)	1296 (38.3)	755 (38.9)
Dyslipidaemia and hypertension, n (%)	716 (21.2)	376 (19.4)
History of cardiovascular disease, n (%)	311 (9.2)	172 (8.9)
SCALE Diabetes (individuals with T2DM)	n = 423	n = 212
Duration of T2DM, years	7.5 (5.7)	6.7 (5.1)
HbA1c, %	7.9 (0.8)	7.9 (0.8)
Fasting plasma glucose, mmol/L	8.8 (1.9)	8.6 (1.8)
HbA1c, glycated haemoglobin; SCALE, Satiety and Clinical Adiposity – Liraglutide Evidence; SD, standard deviation; T2DM, type 2 diabetes mellitus.
Data are presented as mean (SD), unless otherwise stated, and are reported for randomized individuals who were exposed to at least one dose of liraglutide or placebo. Individuals from France did not have to report race. Ethnicity was not collected in the phase 2 trial. Anxiety includes the high level terms 'anxiety symptoms' and 'anxiety disorders not elsewhere classified'. Dyslipidaemia and hypertension were based on reported medical history. Cardiovascular disease was based on standardised (Medical Dictionary for Regulatory Activities; MedDRA) queries ischaemic heart disease, cardiac failure, central nervous system haemorrhages, cerebrovascular conditions, and embolic and thrombotic events.
aIncluding data from the 104-week phase 2 trial and the four phase 3a SCALE trials (one of 160 weeks’ duration, two of 56 weeks and one of 32 weeks). SCALE Obesity and Prediabetes had two parts: a 56-week period for individuals with and without prediabetes. Individuals with prediabetes at screening continued in the second part of the trial for up to 160 weeks of treatment.
bIndividuals without T2DM.
Table 2. Pooled psychiatric and nervous system disorders reported during treatment.
Pooled trialsa	Liraglutide 3.0 mg	Placebo
	N = 3384	N = 1941
Psychiatric disorders	N (%)	E	R	N (%)	E	R
Overall events	412 (12.2)   	557	11.0	206 (10.6)   	273	10.8
Serious events	5 (0.1)	6	0.1	4 (0.2)	4	0.2
Events leading to withdrawal	11 (0.3)	14	0.3	14 (0.7)	15	0.6
Selected types of events		
Depression	101 (3.0)	107	2.1	48 (2.5)	52	2.1
   Serious events	1 (<0.1)	1	<0.1	1 (<0.1)	1	<0.1
Anxiety	92 (2.7)	96	1.9	41 (2.1)	44	1.7
   Serious events	1 (<0.1)	1	<0.1	1 (<0.1)	1	<0.1
Insomnia	122 (3.6)	143	2.8	45 (2.3)	50	2.0
   Serious events	0 (0.0)	0	0.0	0 (0.0)	0	0.0
Nervous system disorders	N (%)	E	R	N (%)	E	R
Overall events	1024 (30.3)	1869	36.9	507 (26.1)	874	34.6
Serious events	18 (0.5)	19	0.4	11 (0.6)	13	0.5
Events leading to withdrawal	30 (0.9)	36	0.7	9 (0.5)	9	0.4
Selected types of events		
Headache	534 (15.8)	820	16.2	273 (14.1)	422	16.7
   Serious events	0 (0.0)	0	0.0	1 (<0.1)	1	<0.1
Memory impairment 	7 (0.2)	7	0.1	1 (<0.1)	1	<0.1
   Serious events	0 (0.0)	0	0.0	0 (0.0)	0	0.0
N, number of individuals; %, percentages are based on total N; E, number of events; R, event rate per 100 person-years; SCALE, Satiety and Clinical Adiposity – Liraglutide Evidence.
Data are using the safety analysis set (all exposed individuals) and show specific preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) database.
aIncluding data from the phase 2 trial up to 52 weeks and four phase 3a SCALE trials (one of 160 weeks’ duration, two of 56 weeks and one of 32 weeks). SCALE Obesity and Prediabetes had two parts: a 56-week period for individuals with and without prediabetes. Individuals with prediabetes at screening continued in the second part of the trial for up to 160 weeks of treatment.






Table 3. PHQ-9 results post-baseline for pooled phase 3a trialsa. 
Baseline PHQ-9 category	End of treatment PHQ-9 category (n (%)) for Liraglutide 3.0 mg (N = 3291) / Placebo (N = 1843)
	None	Mild	Moderate	Moderately severe	Severe
None
Liraglutide 3.0 mgPlacebo	1824 (55.4)1039 (56.4)	564 (17.1)      284 (15.4)	95 (2.9)      49 (2.7)	16 (0.5)      16 (0.9)	5 (0.2)5 (0.3)
Mild
Liraglutide 3.0 mgPlacebo	207 (6.3)      120 (6.5)	313 (9.5)177 (9.6)	89 (2.7)      44 (2.4)	21 (0.6)      6 (0.3)	6 (0.2)      2 (0.1)
Moderate
Liraglutide 3.0 mgPlacebo	22 (0.7)      11 (0.6)	61 (1.9)      35 (1.9)	28 (0.9)27 (1.5)	9 (0.3)      5 (0.3)	4 (0.1)      1 (0.1)
Moderately severeb
Liraglutide 3.0 mgPlacebo	0 (0.0)      2 (0.1)	0 (0.0)      1 (0.1)	0 (0.0)      0 (0.0)	0 (0.0)1 (0.1)	0 (0.0)      0 (0.0)
PHQ-9, Patient Health Questionnaire-9; SCALE, Satiety and Clinical Adiposity – Liraglutide Evidence.
Data are using the safety analysis set (all exposed individuals), and show the shift from randomization to maximum PHQ-9 total score during treatment. Blue shading represents improvement and grey shading, worsening. No shading denotes no change. No individuals were in the severe category at randomization.
Total for no change was 2167 (65.8%) in the liraglutide group and 1247 (67.7%) in the placebo group. Total improved was 290 (8.8%) versus 169 (9.2%). Total worsened was 809 (24.6%) versus 412 (22.4%). Total missing was 25 (0.8%) versus 15 (0.8%).
The total score of the 9 items ranges from 0 to 27; total scores of 0–4 represent no depression, 5–9 represents mild depression, 10–14 represents moderate depression, 15–19 represents moderately severe depression and 20–27 represents severe depression. A PHQ-9 score ≥15 at screening was exclusionary. 
aIncluding data from the four phase 3a SCALE trials (one of 160 weeks’ duration, two of 56 weeks and one of 32 weeks). SCALE Obesity and Prediabetes had two parts: a 56-week period for individuals with and without prediabetes. Individuals with prediabetes at screening continued in the second part of the trial for up to 160 weeks of treatment.
bThree individuals changed to the moderately severe category (which was exclusionary at screening) between screening and baseline.




Table 4. C-SSRS results post-baseline.
Pooled phase 3a trialsa	Liraglutide 3.0 mg	Placebo 
	N = 3291	N = 1843
Number of participants completing C-SSRS	3270	1832
N (%) with suicidal ideation on the C-SSRS	34 (1.03)	19 (1.03)
1. Wish to be dead	30 (0.91)	18 (0.98)
2. Active suicidal ideation, non-specific thoughts	15 (0.46)	8 (0.43)
3. Active suicidal ideation, any method (no plan)
    without intent	11 (0.33)	3 (0.16)
4. Active suicidal ideation, some intent to act,
    without specific plan	2 (0.06)	1 (0.05)
5. Active suicidal ideation, specific plan and intent	1 (0.03)	2 (0.11)
C-SSRS, Columbia-Suicide Severity Rating Scale; N (%), number and percentage of individuals; SCALE, Satiety and Clinical Adiposity – Liraglutide Evidence.
Data are using the safety analysis set (all exposed individuals) and represent responses obtained at any time during treatment. The number and percentage of specific ideation types sum to more than that of any ideation because individuals may have more than one type over time.
aIncluding data from the four phase 3a SCALE trials (one of 160 weeks’ duration, two of 56 weeks and one of 32 weeks). SCALE Obesity and Prediabetes had two parts: a 56-week period for individuals with and without prediabetes. Individuals with prediabetes at screening continued in the second part of the trial for up to 160 weeks of treatment.





PAGE  



17



